MJFF Awards $710,000 to Advance Understanding of Parkinson's Disease Subtypes
“One of the most frustrating aspects of Parkinson’s disease — for patients, researchers and clinicians alike — is the significant variability in how the disease manifests itself from patient to patient,” said Sarah Orsay, chief executive officer of the Foundation. “The retrospective studies funded under PD Subtypes aim to analyze data already gathered on different forms of the disease. This analysis could yield valuable information with potential to improve clinicians’ ability to treat patients with existing therapies. It could also advance development of new treatments and enable better design of future clinical trials.”
Applicants under PD Subtypes were required to propose research that would make use of existing data from well-characterized populations of Parkinson’s patients. Several researchers will mine specific databases established by their own institutions for various purposes. Others will work from some of the most important clinical research populations in the Parkinson’s field, including the DATATOP (Deprenyl and Tocopherol
Antioxidative Therapy of Parkinsonism) study population of 800 early-stage Parkinson’s patients and the PRECEPT (Parkinson Research Examination of CEP-1347 Trial) population of 800 patients.
Nick Holford, MBChB, FRACP, of the
Connie Marrras, MD, PhD FRCP(C), of Toronto Western Hospital will focus on determining predictive factors for reaching a common neuroprotective clinical trial endpoint — time to disability requiring dopamine replacement therapy. She will use PRECEPT data to validate an earlier study she conducted in the DATATOP population. This previous study examined factors including smoking, disease duration, and tremor as an initial symptom.
Stephen Van Den Eeden, PhD, of the Kaiser Foundation Research Institute will assess predictive factors — including age at diagnosis, gender, family history and race — that may bear on mortality in Parkinson’s disease.
Other funded studies will examine aspects of PD including whether it is possible to identify PD subgroups based on areas of disability (cognitive, balance, motor function) seen at the last available clinical visit; and factors (such as mood analysis, sleep, cognitive function and pain) that may contribute to the identification of novel PD subtypes.
Leadership funding for PD Subtypes was provided by the Kinetics Foundation of Los Altos, California. “We look forward to a continuing partnership between The Michael J. Fox Foundation for Parkinson’s Research and the Kinetics Foundation as we work to improve PD diagnosis and treatment by characterizing disease subtypes,” said Ken Kubota, Kinetics’ director of programs.
A full list of awardees is below. To read grant abstracts and researcher bios, please visit The Michael J. Fox Foundation’s Web site at www.michaeljfox.org.
“Evaluating novel predictors of Parkinson’s disease progression”
Stephen Grill, MD, PhD, Parkinson’s and Movement Disorders Center of Maryland
Marc Weisskopf, PhD, ScD,
“Defining PD subtypes based on patterns of long-term outcomes”
Robert Hauser, MD, MBA,
“Prediction of death, dementia, disability, depression from the time course of UPDRS motor status”
Nick Holford, MBChB, FRACP,
“Longitudinal changes in patterns of motor UPDRS subscores”
Sue Leurgens, PhD,
“Prognostic factors in early Parkinson’s disease”
Connie Marras, MD, PhD FRCP(C),
“Do clinical and environment characteristics at PD diagnosis predict survival?”
Stephen Van Den Eeden, PhD, Kaiser Foundation Research Institute
Jacobus J. Van Hilten, MD, PhD,